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Abstract (194 words)  
The standard dose of imatinib for treatment of chronic-phase chronic myeloid 
leukemia (CML) is 400 mg/day. Some patients receive reduced doses of imatinib 
because of serious adverse effects. Recently, the effective plasma threshold for 
trough imatinib levels was demonstrated to be 1,002 ng/ml. In this study, we 
evaluated the association of an imatinib dose with trough plasma concentrations 
and clinical outcomes in 31 patients with chronic-phase CML who were treated 
at Kumamoto University Hospital. Twenty-seven patients were optimally treated 
with various doses of imatinib. The mean (±SD) trough plasma concentrations of 
imatinib were 1.40 ± 0.57 µg/ml in 13 patients receiving 400 mg/day and 1.15 ± 
0.44 µg/ml in 9 patients receiving 300 mg/day as an optimal dose. Mean trough 
levels of the two groups were not significantly different and exceeded the 
effective plasma threshold. Body surface area (BSA) was significantly smaller in 
patients receiving the reduced dose compared with those receiving the standard 
dose (p=0.001). The optimal imatinib dose was associated with age and gender 
as well as BSA. A reduced dose of 300 mg/day of imatinib may be sufficient for 
treatment of CML patients with smaller body size, particularly when intolerability 
arises.  
 
Keywords: Chronic myeloid leukemia, imatinib, optimal dose, body surface area 
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1 Introduction 
Imatinib mesylate, an inhibitor specific for the TK domain in the Abelson 
proto-oncogene, c-kit, and platelet-derived growth factor receptor, has been 
shown to be highly effective in the treatment of patients with chronic myeloid 
leukemia (CML) and gastrointestinal stromal tumors [1-4]. Based on the IRIS 
study [2, 3], the established standard dose of imatinib is 400 mg/day for patients 
with chronic-phase CML. This dose is well tolerated by most patients, and 
plasma trough levels are dose-proportional for the dose range of 25 to 1,000 
mg/day [5]. The relationship between pharmacokinetics and pharmacodynamics 
of imatinib at steady state indicates that clinical response is highly dependent on 
the administered dose for patients with CML, and that a dose of 400 mg/day or 
higher is required for maximal clinical outcomes [1, 5, 6]. Recently, Picard et al 
demonstrated that trough imatinib plasma levels at steady-state must exceed 
1,002 ng/ml to obtain the best sensitivity in CML patients, and that the plasma 
imatinib concentrations are associated with clinical response [7]. Similarly, 
Larson et al reported on the pharmacokinetics of imatinib and their correlation 
with clinical response during 5 years of follow-up in the IRIS study [8].  These 
authors indicated that maintaining plasma trough levels at or above 1,002 ng/ml 
may be important for achieving a complete cytogenetic response (CCR) and a 
major molecular response (MMR).  
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  The recommended dose of 400 mg/day imatinib sometimes causes severe 
adverse effects such as mylelo-supression, edema, and skin rash, which in turn 
may lead to poor compliance, premature cessation of treatment, and failure of 
therapy. To avoid these unfavorable clinical situations, the daily dose of imatinib 
is often reduced from 400 to 200-300 mg/day in clinical practice  [9-11], although 
maintaining a low dose of imatinib is not generally recommended. Recently, 
Ohnishi et al suggested that a reduced dose of 300 mg/day imatinib might be 
enough to achieve a CCR in some Japanese patients, and a weak 
inverse-correlation was observed between imatinib trough levels and body 
weight [12]. However, it is not known whether the plasma concentrations of 
imatinib reach the effective level (1,002 ng/ml) in such patients having a 
favorable response to a reduced dose of imatinib. Indeed, there are little data on 
the pharmacokinetics and pharmacodynamics of patients given a reduced dose 
of imatinib. To clarify the relationship of the optimal dose of imatinib with trough 
levels of imatinib at steady state, we measured plasma concentrations of 
imatinib in chronic-phase CML patients responding to a reduced dose of 300 
mg/day as well as to a standard dose of 400 mg/day and analyzed differences in 
patient characteristics between these two patient groups. 
 
2 Materials and Methods 
2.1 Patients and treatment 
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Plasma concentrations of imatinib at steady state (on day 30 of treatment or 
later) were assessed in 31 patients with chronic-phase CML who were followed 
up at Kumamoto University Hospital during 2003 to 2007. All patients were 
initiated with the standard-dose of 400 mg/day imatinib. In case of severe 
adverse drug events (Grade 2 or more on the Common Toxicity Criteria of the 
National Cancer Institute), imatinib was reduced to 100 to 300 mg/day or 
temporally discontinued until adverse events were ceased, and resumed from a 
low dose and increased gradually up to a tolerable dose. When adverse events 
(≥ Grade 2) repeated, low dose imatinib (200 or 300 mg/day) was continued with 
carefull monitoring of imatinib response. In contrast, imatinib dose was escalated 
up to 800 mg/day if an optimal response (CCR) was not achieved after treatment 
with 400 mg/day imatinib for one year. Dose of imatinib that could achieve and 
maintain a CCR during the observation period was defined as “an optimal dose” 
in this study. Approval from the ethics committee in Kumamoto University 
Hospital was obtained, and all patients provided informed consent to participate 
in this study, which was performed in accordance with the Declaration of Helsinki.  
Cytogenetic responses to imatinib were assessed using a conventional 
cytogenetic analysis of bone marrow metaphases. CCR was defined as 0% of 
Philadelphia chromosome-positive cells in bone marrow aspirate. To assess 
molecular responses, total RNA was extracted from peripheral blood cells or 
bone marrow cells, and BCR-ABL transcript levels were quantified using 
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real-time quantitative PCR.  Three or more log reduction in the transcript levels 
was determined to be a major molecular response (MMR). 
 
2.2 Pharmacokinetic sample analysis 
Blood samples were collected at steady state (day 30 of treatment or later) prior 
to the morning dose (trough plasma levels). Plasma levels of imatinib were 
determined using high performance liquid chromatography as described 
previously [13]. Briefly, EDTA-containing blood samples (5 ml) were collected 
from patients at steady state and were immediately centrifuged (1500 g, 5 min at 
4ºC) to obtain the plasma fraction. The separated plasma was stored at -80°C 
until measurement of plasma imatinib concentrations. 
 
2.3 Statistical analysis 
Data on trough plasma levels of imatinib are presented as mean values with 
95% confidence intervals (CI). The t test was used to determine differences in 
imatinib trough levels between different dose groups. Fisherʼs exact test was 
used to evaluate the association of an optimal dose at steady state with gender, 
age at starting treatment (below or above the median value of 53 years), body 
surface area (BSA; below or above the median value of 1.68 m2), and prior 
interferon (IFN) treatment. JMP ver. 7 (SAS Institute Inc., Cary, NC) was used for 
all statistical analyses. A p value <0.05 was considered statistically significant.   
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3 Results  
3.1 Patient characteristics 
The characteristics of the 31 patients are shown in Table 1. The median age was 
49 years (range, 24-80), with 18 males and 13 females. All patients showed 
adequate hepatic and renal functions: mean values (95% CIs) of ALT, AST, total 
bilirubin, BUN, serum creatinine, and serum albumin were 23 (20-26) IU/L, 24 
(18-30) IU/L, 0.5 (0.5-0.6) mg/dL, 14.0 (12.6-15.4) mg/dL, 0.82 (0.74-0.91) 
mg/dL and 4.4 (4.3-4.5) g/dL, respectively. Each of the patients started with the 
standard recommended daily dose (400 mg) of imatinib. However, the daily dose 
was subsequently modified according to individual requirements. The main 
reasons for dose reduction were cytopenia, gastrointestinal symptoms, such as 
diarrhea and nausea, or development of a skin rash (Table 1).  Of the 31 patients, 
4 patients discontinued imatinib: 2 patients could not tolerate even 200 mg/day 
imatinib due to severe cytopenia; one patient developed a concomitant unrelated 
disease (lung cancer); one patient showed imatinib-resistance and was enrolled 
to a clinical trial for a second-generation tyrosine kinase inhibitor. 
 
3.2 Imatinib dose and clinical outcome 
Twenty-seven patients tolerated the drug well and showed clinical benefit: 13 
patients were maintained with imatinib at a standard dose of 400 mg/day, 9 
patients were treated at a reduced dose of 300 mg/day, and 5 patients received 
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a high dose of 500 or 600 mg/day. All of 27 patients achieved a CCR and 
sustained this favorable response during the follow-up period, indicating that the 
dosage of imatinib was considered optimal for individual patients. 16 (59%) of 27 
patients with CCR achieved a MMR, but there was no significant difference in 
MMR rates between patients receiving 300 mg/day imatinib and those receiving 
400 mg/day imatinib. None of the patients receiving 300 mg/day imatinib showed 
signs of disease progression.  
3.3 Trough plasma concentrations of imatinib at different doses 
The relationship between dose and plasma trough level at steady state is shown 
in Figure 1. The increase in mean plasma level was proportional to the dose of 
imatinib. Mean (± SD) trough plasma levels of imatinib at a standard dose of 400 
mg/day were 1.40 ± 0.57 µg/ml (n=13, 95% CI 1.33-1.47 µg/ml). Trough levels at 
a reduced dose of 300 mg/day were 1.15 ± 0.44 µg/ml (n=9, 95% CI 1.05-1.25 
µg/ml). There was no significant difference in plasma trough levels between 
patients receiving 300 mg/day and 400 mg/day (p=0.26). Both mean plasma 
concentrations exceeded the effective plasma threshold for trough imatinib 
levels (1,002 ng/ml), which was proposed by Picard et al to give a favorable 
response [7]. In contrast, a dose of 200 mg/day did not reach the effective 
plasma concentration.  Five patients achieved a CCR at a dose of 500 or 600 
mg/day without developing serious adverse effects.  There was no relationship 
between trough plasma levels and severity of adverse events (data not shown: 
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see supplement Figure).   Interestingly, mean trough levels of imatinib tended to 
be higher in patients with MMR (1.642 ± 0.709 µg/mL) than those with CCR 
(1.467 ± 0.494 µg/mL).  
 
3.4 Relationship between optimal dose of imatinib and BSA  
It is clinically important to clarify the reason why low-dose imatinib was sufficient 
in a proportion of our patients to reach the effective plasma trough concentration. 
Recently, a weak correlation between steady-state trough levels of imatinib and 
BSA was identified and imatinib exposure (area under the curve or plasma 
concentration) was dose proportional in a subanalysis of the IRIS study [8]. 
Considering the lower median BSA in the present study (male, 1.76 m2; female 
1.44 m2) as compared with that in the IRIS study (male, 2.0; female, 1.75 m2), 
the optimal dose of imatinib may be correlated with BSA. Thus we evaluated the 
relationship of BSA with optimal dose (300 mg/day vs. 400 mg/day) of imatinib.  
As shown in Figure 2, the median (±SD) BSA of patients receiving 300 mg/day 
was significantly smaller than that of patients receiving 400 mg/day (1.46 ± 0.16 
vs. 1.76 ± 0.15 m2, p=0.001). Because older and/or female Japanese individuals 
generally have a small body size [9], we further evaluated the associations of an 
optimal dose (300 vs. 400, 500, and 600 mg/day) with age, gender, prior 
treatment with IFN, and BSA (Table 2). An optimal dose of imatinib was 
significantly associated with age (p=0.009), gender (p=0.034), and BSA 
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(p=0.004), but not with prior IFN therapy. Thus, the present data suggest that an 
optimal dose of imatinib can be set lower than the standard dose of 400 mg/day 
in smaller or older female patients. 
 
Discussion 
The standard 400 mg/day dose of imatinib is well tolerated for chronic-phase 
CML patients. Despite its favorable efficacy, reduced doses of imatinib are 
sometimes used because of severe toxicity issues [9]. In fact, 8% of patients 
received less than 400 mg/day during the 5-year follow-up in the IRIS study [3]. 
The mean daily dose for Japanese patients with early chronic-phase CML was 
reported to be relatively lower: 300 mg in 27% and 200 mg or lower in 20% [12]. 
In the present study, 9 (33.3%) out of 27 patients who achieved a CCR had been 
treated with imatinib at 300 mg/day. Importantly, the mean trough level of 
imatinib of the patients exceeded the effective plasma threshold (1,002 ng/ml), 
suggesting that monitoring of imatinib plasma concentrations may be beneficial 
to predict a clinical outcome when a reduced dose of imatinib is considered in a 
clinical setting. 
 
The correlation of imatinib dose with trough imatinib concentrations was 
comparable to the IRIS study [8]; however, the mean (± SD) trough plasma 
concentration of imatinib at 400 mg/day was much higher in our study (1.40 ± 
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0.57 µg/ml) than in the IRIS study (0.98 ± 0.53 µg/ml). This difference is partly 
explained by smaller BSA of our cohort as compared with that of the IRIS study, 
because a weak inverse-correlation was observed between trough 
concentrations of imatinib and BSA in the large-scale study [8]. Racial disparities 
of BSA may be related with a disparity in trough concentrations of imatinib 
between Asian and American or European subjects. 
 
Our study indicated that BSA was significantly lower in patients receiving 300 
mg/day imatinib as an effective dose than 400 mg/day. By considering BSA with 
trough concentrations, a dose of 300 mg/day seems to be enough to obtain the 
therapeutic efficacy equivalent to the standard dose of 400 mg/day in patients 
with small body size, because the plasma trough level of imatinib would exceed 
the therapeutic concentration (1,002 ng/ml). Similar results have been reported 
from Asian countries: a lower dose of imatinib (200-300 mg/day) led to clinical 
benefits in five Japanese CML patients with low BSA (median value, 1.46 m2) 
[9]; Korean CML patients with low BSA (median value, 1.55 m2) benefited from 
300 mg/day imatinib [10]. Taken together, these observations suggest that the 
standard dose of 400 mg/day imatinib may be too high as an optimal dose for a 
proportion of patients with chronic phase CML having low BSA and that such 
patients can be optimally managed with reduces doses of imatinib if the effective 
imatinib trough levels are sustained. Thus, individualized dose optimization 
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based on plasma imatinib concentrations is considered a key feature of imatinib 
therapy in patients with CML, particularly when intolerability arises [14].  
 
We did not evaluate the association between an optimal dose of imatinib with 
drug-metabolizing enzymes and drug transporter genotypes. Previous reports 
demonstrated an association between the pharmacokinetics of imatinib and ABC 
transporters (ABCB1, ABCC1, ABCG2), human organic cation transporter 
(OCT1), and cytochrome P450 isoenzymes, such as CYP2C9 and CYP3A4/5 
[15-18].  The role of the genetic variants and race differences in inter-individual 
variability in imatinib pharmacokinetics remains controversial, and further 
investigations are needed to determine the relative role of genetic variation and 
BSA variability on the optimal dose and pharmacokinetics of imatinib.  
 
In summary, the imatinib dose that could give an optimal response with tolerable 
adverse effects was significantly associated with BSA, age or gender in our 
cohort. A reduced dose of 300 mg/day imatinib may be sufficient for the 
treatment of CML patients with small body size. To avoid insufficient efficacy at 
reduced doses, monitoring of plasma imatinib levels is recommended. A 
proposed algorithm for management of CML patients on the basis of therapeutic 
drug monitoring of imatinib may help to make a proper clinical decision, when 
imatinib dose modification is required in the clinical setting (Figure 3).  Further 
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studies on a larger cohort of CML patients for a longer follow-up period are 
needed to confirm the relationship of the optimal dose with BSA and trough 
plasma concentrations of imatinib.  
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Titles and legends to figures 
 
Figure 1. Relationship of trough plasma concentrations of imatinib at 
steady state with administered dose 
Each point represents the mean (± SD) plasma imatinib trough concentration. 
 
Figure 2. Comparison of body surface area (BSA) between patients 
receiving 300 mg/day vs 400 mg/day imatinib as an optimal dose 
Boxes represent the distribution of the 25th and 75th percentiles; lines within 
boxes represent median values. Bars represent ranges. 
 
Figure 3. A proposed model of CML patient management on the basis of 
therapeutic drug monitoring (TDM) of imatinib 
*Patients who are unable to maintain the initial dose of 400 mg daily due to 
persistant adverse effects (usually ≥ Grade 2). 
**Number of patients examined in the present study is indicated in parenthesis 
for reference. One patient discontinued 300 mg imatinib before the sixth month 
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evaluation for cytogenetic response due to chemotherapy for concomitant lung 
cancer.  
*** Target Cmin: Target trough concentration of imatinib. 1,002 ng/mL is 
recommended as target Cmin according to reference no.7 and no.8. 
 
Table 1. Characteristics of the 31 patients treated with imatinib 
Daily dose of imatinib at steady state (median ± SD) Characteristic Total 200mg 300mg 400mg >500mg 
Gender (no.) 
Male 
Female 
 
18 
13 
 
0 
2 
 
3 
7 
 
10 
3 
 
5 
1 
Body surface area (m2) 
Median (male; female) 
Range 
 
1.68 (1.76; 1.44) 
1.28-2.02 
 
1.35, 1.58 
 
1.45 ± 0.14 
 
1.76 ± 0.14 
 
1.76 ± 0.18 
Age at diagnosis (years) 
Median 
Range 
 
49 
24-80 
 
42, 71 
 
58 ± 10 
 
41 ± 11 
 
41 ± 9 
Age at starting treatment (years) 
Median 
Range 
 
52 
24-85 
 
42, 75 
 
62 ± 9 
 
46 ± 12 
 
48 ± 8 
Duration of treatment (months) 
Median 
Range 
 
45 
5-72 
 
16, 30 
 
44 ± 21 
 
52 ± 21 
 
34 ± 20 
Prior interferon-α treatment (no.) 
Yes (no. of CCR) 
No 
 
16 (7) 
15 
 
1 
1 
 
5 (3) 
5 
 
6 (2) 
7 
 
4 (2) 
2 
Response to imatinib 
MMR 
CCR 
Resistance a 
Intolerance b 
Unable to evaluate c 
 
16 
11 
1 
2 
1 
 
 
 
 
2 
 
 
5 
4 
 
 
1 
 
10 
3 
 
 
 
 
1 
4 
1 
 
 
Imatinib-related adverse events (no.) d 
Edema 
Skin rash 
Cytopenia 
Gastrointestinal  
Myalgia or muscle cramp 
Renal dysfunction 
 
15 / 0 
10 / 1 
4 / 4 
9 / 0 
4 / 0 
1 / 0 
 
0 / 0 
1 / 0 
0 / 1 
1 / 0 
0 / 0 
0 / 0 
 
4 / 0 
2 / 1 
2 / 3 
3 / 0 
2 / 0 
1 / 0 
 
8 / 0 
4 / 0 
1 / 0 
2 / 0 
1 / 0 
0 / 0 
 
3 / 0 
3 / 0 
1 / 0 
3 / 0 
1 / 0 
0 / 0 
CCR, complete cytogenetic response; MMR, major molecular response 
a One patient with no cytogenetic response after 12 months of 800 mg/day imatinib. 
b Two patients had intolerable side effects despite a reduced imatinib dose of 200 mg/day. These 3 patients (2 with intolerable side 
effects and 1 with no response) ceased imatinib therapy. 
c A patient discontinued 300 mg/day imatinib before the sixth month evaluation for cytogenetic response due to chemotherapy for 
concomitant lung cancer. 
d Values represent grade 1 or 2 / grade 3 or 4 
 
Table 2. Correlation of an optimal dose of imatinib with gender, age, body 
surface area (BSA), and prior interferon (IFN) treatment 
 
 
Characteristic 
Reduced dose 
(300 mg/day, 
n=9) 
Standard dose or higher 
(400 mg/day, n=13; 500 or  
600 mg/day, n=5) 
P valuea 
Gender  
Male 
Female  
% of females 
 
3 
6 
66.7% 
 
14 
4  
22.2% 
 
 
 
0.034  
Age (years)b  
>=53 
<53 
% of older than 53 
 
8 
1 
88.9% 
 
6 
12 
33.3% 
 
 
 
0.009  
BSA (m2)  
>=1.68 
<1.68 
% of less than 1.68 
 
1 
8 
88.9% 
 
13 
5 
27.8% 
 
 
 
0.004 
Prior IFN therapy 
 Yes 
No 
% of yes 
 
5 
4 
55.6% 
 
10 
8 
55.6% 
 
 
 
0.66  
All patients at reduced dose (300 mg/day), standard dose (400 mg/day), and higher 
dose (500 or 600 mg/day) achieved a CCR or a MMR without developing severe 
adverse events during treatment with imatinib. 
aFisherʼs exact test was used to evaluate the association of an optimal dose with gender, 
age, BSA, and prior IFN treatment. 
bMedian age at starting imatinib treatment was 53 years olds. 
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